Pleurisy Market Size, Share, Growth, and Industry Analysis, By Type (Thoracentesis, Video-Assisted Thoracic Surgery, Imaging Devices, Blood Test), By Application (Hospital, Clinics, Diagnostics Laboratories), Regional Insights and Forecast to 2035

Pleurisy Market Overview

The global Pleurisy Market size estimated at USD 2619.34 million in 2026 and is projected to reach USD 4789.71 million by 2035, growing at a CAGR of 6.94% from 2026 to 2035.

The Pleurisy Market is a specialized segment of the respiratory and thoracic disease management industry focused on diagnosis, monitoring, and treatment of pleural inflammation and related complications. Pleurisy affects millions of patients annually, with pleural effusion occurring in approximately 1.5 million cases each year in developed healthcare systems. More than 65% of pleurisy cases are associated with infections, autoimmune disorders, pulmonary embolism, or malignancies. Diagnostic imaging remains the primary assessment tool, utilized in over 85% of suspected cases. Thoracentesis procedures exceed 1 million annually worldwide. Increasing adoption of minimally invasive thoracic interventions and advanced diagnostic technologies continues to support the expansion of the Pleurisy Market.

The United States represents a major healthcare market for pleurisy diagnosis and treatment. More than 1.5 million patients develop pleural effusion annually, creating substantial demand for imaging and thoracic procedures. Approximately 70% of pleurisy-related diagnoses involve chest imaging techniques such as X-ray, CT scan, and ultrasound. Hospitals perform over 175,000 thoracentesis procedures each year. Lung infections contribute to nearly 40% of pleurisy-related hospital admissions, while autoimmune disorders account for approximately 15%. More than 6,000 acute care hospitals provide pleurisy management services. Continued growth in advanced diagnostic capabilities and minimally invasive thoracic surgery supports strong demand across healthcare facilities.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Respiratory disease prevalence contributes 68%, diagnostic imaging utilization reaches 85%, hospital-based treatment accounts for 72%, thoracic procedure adoption exceeds 54%, and chronic pulmonary disorder incidence contributes 47%.
• Major Market Restraint: Late diagnosis affects 33%, treatment delays account for 28%, healthcare access limitations reach 24%, procedural complications contribute 12%, and diagnostic variability impacts 19%.
• Emerging Trends: Ultrasound-guided procedures exceed 61%, minimally invasive surgery adoption reaches 48%, advanced imaging utilization accounts for 73%, digital diagnostics contribute 35%, and precision monitoring technologies represent 29%.
• Regional Leadership: North America accounts for 39%, Europe contributes 28%, Asia-Pacific represents 24%, Middle East & Africa hold 9%, and hospital treatment utilization exceeds 72%.
• Competitive Landscape: The top five suppliers control 57%, thoracic instrument manufacturers contribute 63%, imaging technology providers account for 52%, surgical equipment companies represent 41%, and specialized device suppliers hold 34%.
• Market Segmentation: Imaging devices account for 38%, thoracentesis contributes 27%, blood tests represent 19%, video-assisted thoracic surgery accounts for 16%, and hospital applications exceed 66%.
• Recent Development: Imaging accuracy improved by 21%, minimally invasive procedure adoption increased 26%, ultrasound-guided interventions expanded 31%, thoracic device innovation reached 18%, and diagnostic workflow efficiency improved 24%.

Pleurisy Market Latest Trends

The Pleurisy Market is evolving through advances in diagnostic imaging, minimally invasive procedures, and patient monitoring technologies. More than 85% of suspected pleurisy cases now undergo imaging evaluation before treatment planning. Ultrasound-guided thoracentesis procedures have increased significantly and currently account for approximately 61% of interventions due to improved procedural accuracy and lower complication rates. Computed tomography utilization has expanded across healthcare facilities, with nearly 73% of complex pleural disease cases receiving advanced imaging evaluation. Portable ultrasound devices are increasingly deployed in emergency departments and intensive care units, improving diagnostic accessibility by approximately 28%.

Video-assisted thoracic surgery has become a preferred treatment approach in selected cases involving recurrent pleural effusions and diagnostic uncertainty. More than 48% of thoracic surgeons utilize minimally invasive techniques as first-line procedural options. Digital imaging platforms have reduced diagnostic review times by approximately 22%. Healthcare providers are also integrating artificial intelligence-assisted image interpretation systems capable of improving lesion detection rates by 17%. Blood-based inflammatory markers continue gaining importance in pleurisy assessment, supporting early disease identification. These technological advancements are enhancing diagnostic accuracy, treatment efficiency, and patient outcomes across the global Pleurisy Market.

Pleurisy Market Dynamics

DRIVER

"Rising prevalence of respiratory and pleural disorders."

Increasing incidence of respiratory infections, autoimmune diseases, pulmonary embolism, and thoracic malignancies remains the primary growth driver for the Pleurisy Market. More than 300 million individuals worldwide suffer from chronic respiratory diseases, creating a substantial patient pool vulnerable to pleural complications. Approximately 40% of pleurisy cases are linked to bacterial and viral infections. Lung cancer affects over 2 million patients annually and frequently contributes to pleural effusion development. Healthcare systems report more than 1.5 million pleural effusion cases each year in major developed regions. Improved awareness, increasing diagnostic accessibility, and rising adoption of thoracic interventions continue driving demand for pleurisy-related diagnostic and treatment solutions.

RESTRAINT

"Delayed diagnosis and limited access to specialized care."

Diagnosis of pleurisy can be challenging because symptoms often overlap with pneumonia, pulmonary embolism, and cardiovascular disorders. Approximately 33% of patients experience diagnostic delays before receiving definitive evaluation. Rural healthcare facilities frequently face limited access to advanced imaging systems and thoracic specialists. Nearly 24% of patients in underserved regions encounter delays in specialist referral. Procedural complications associated with invasive interventions affect approximately 12% of cases. Limited availability of trained thoracic surgeons and specialized diagnostic equipment can also restrict treatment accessibility. These factors continue influencing healthcare outcomes and slowing adoption of advanced pleurisy management technologies in several regions.

OPPORTUNITY

"Expansion of minimally invasive thoracic procedures."

Minimally invasive technologies create substantial opportunities within the Pleurisy Market. Video-assisted thoracic surgery reduces hospital stays by approximately 35% compared with traditional open thoracic procedures. More than 48% of thoracic surgical interventions now utilize minimally invasive approaches. Ultrasound-guided thoracentesis improves procedural success rates above 95% while reducing complication incidence. Healthcare facilities increasingly invest in portable imaging systems and advanced thoracic instruments. Digital diagnostics and artificial intelligence-assisted image interpretation further support early detection and treatment planning. Expanding adoption of minimally invasive thoracic procedures is expected to improve patient outcomes and increase utilization of specialized devices and diagnostic technologies.

CHALLENGE

"Managing complex underlying disease conditions."

Pleurisy often occurs as a secondary complication of infections, autoimmune disorders, malignancies, and cardiovascular diseases, making diagnosis and treatment more complex. Approximately 65% of cases are associated with underlying systemic conditions requiring multidisciplinary management. Patients with malignant pleural effusions frequently require repeated interventions, increasing healthcare utilization. Autoimmune disorders contribute to approximately 15% of pleural inflammation cases and often require long-term monitoring. Differentiating between infectious and noninfectious causes can extend diagnostic timelines by several days. Healthcare providers must balance rapid symptom management with comprehensive investigation of underlying conditions. These complexities continue presenting challenges for effective pleurisy diagnosis and treatment.

Pleurisy Market Segmentation

Download FREE Sample to learn more about this report.

The Pleurisy Market is segmented by type and application. Imaging devices account for approximately 38% of market activity because imaging remains the primary diagnostic approach in pleural disease evaluation. Thoracentesis contributes 27% due to widespread utilization in fluid drainage and diagnostic sampling. Blood tests represent 19% of demand, supporting inflammatory and infectious disease assessment. Video-assisted thoracic surgery accounts for 16% and continues expanding through minimally invasive treatment adoption. By application, hospitals represent approximately 66% of total utilization, clinics contribute 22%, and diagnostic laboratories account for 12%. Technological advancements continue supporting growth across all major segments.

BY TYPE

Thoracentesis: Thoracentesis accounts for approximately 27% of the Pleurisy Market and remains one of the most frequently performed pleural procedures. More than 1 million thoracentesis procedures are conducted annually worldwide for diagnostic and therapeutic purposes. Ultrasound guidance is utilized in approximately 61% of procedures, improving success rates above 95%. Thoracentesis enables removal of pleural fluid volumes exceeding 1,000 milliliters in many cases, providing rapid symptom relief. Hospitals account for approximately 72% of procedure volume. Increasing prevalence of pleural effusion and growing adoption of image-guided interventions continue supporting strong demand for thoracentesis equipment and related consumables across healthcare facilities.

Video-Assisted Thoracic Surgery: Video-assisted thoracic surgery represents approximately 16% of market activity and is increasingly utilized for pleural biopsies, recurrent pleural effusion management, and complex diagnostic evaluations. More than 48% of thoracic surgeons prefer minimally invasive techniques for eligible patients. Video-assisted thoracic surgery reduces postoperative hospital stays by approximately 35% and decreases complication rates by 18% compared with traditional thoracotomy procedures. Advanced endoscopic visualization systems provide image magnification exceeding 10 times, improving procedural precision. Increasing adoption of minimally invasive surgical technologies and growing availability of specialized thoracic instruments continue driving expansion within this segment.

Imaging Devices: Imaging devices dominate the market with approximately 38% share due to their essential role in diagnosis and treatment planning. More than 85% of suspected pleurisy cases undergo chest imaging evaluation. Chest X-rays account for approximately 62% of initial assessments, while computed tomography contributes 23% and ultrasound accounts for 15%. Portable ultrasound systems have improved point-of-care diagnostic accessibility by nearly 28%. Advanced imaging technologies improve pleural lesion detection rates by approximately 21%. Hospitals and emergency departments remain the largest users of imaging equipment. Continuous innovation in digital imaging and artificial intelligence-assisted diagnostics supports strong growth in this segment.

Blood Test: lood tests contribute approximately 19% of total market demand and support diagnosis of inflammatory, infectious, and autoimmune causes of pleurisy. More than 70% of patients undergo blood-based laboratory evaluation during diagnostic assessment. Inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate are frequently utilized in clinical practice. Blood tests assist physicians in identifying bacterial infections, autoimmune diseases, and systemic inflammatory conditions associated with pleural disease. Diagnostic laboratories process millions of pleurisy-related blood samples annually. Improvements in biomarker identification and laboratory automation continue enhancing the role of blood testing in pleurisy diagnosis and ongoing patient management.

BY APPLICATION

Hospital: Hospitals represent approximately 66% of the Pleurisy Market and remain the primary setting for diagnosis, treatment, and management of pleural diseases. More than 85% of thoracentesis procedures are performed in hospital environments due to the availability of imaging equipment, surgical facilities, and multidisciplinary care teams. Over 6,000 acute care hospitals in major developed healthcare systems provide pleurisy-related services. Approximately 72% of patients with severe pleural effusion require hospitalization for diagnostic evaluation and treatment. Advanced imaging technologies, including CT scanners and ultrasound systems, are available in more than 90% of tertiary hospitals. Increasing admissions related to respiratory infections, lung cancer, and autoimmune disorders continue driving demand for pleurisy management services in hospitals worldwide.

Clinics: Clinics account for approximately 22% of the Pleurisy Market and play an important role in early diagnosis, follow-up care, and outpatient management. More than 40% of patients with mild pleuritic symptoms initially seek evaluation through outpatient clinics. Pulmonary specialty clinics conduct approximately 35% of follow-up assessments for pleural disorders. Portable ultrasound systems are currently utilized in nearly 28% of advanced respiratory clinics, improving diagnostic efficiency. Clinics contribute significantly to chronic disease monitoring, especially for patients with autoimmune-related pleurisy. Increasing healthcare decentralization and expansion of outpatient respiratory services continue strengthening the role of clinics within the Pleurisy Market.

Diagnostics Laboratories: Diagnostic laboratories represent approximately 12% of total market activity and support blood testing, pleural fluid analysis, microbiological testing, and biomarker assessment. More than 70% of pleurisy patients undergo laboratory testing during the diagnostic process. Cytological examination of pleural fluid is performed in approximately 55% of thoracentesis cases. Laboratory analysis assists in differentiating infectious, malignant, and inflammatory causes of pleural disease. Automated diagnostic platforms improve sample processing efficiency by nearly 24%. Growing utilization of molecular diagnostics and inflammatory biomarkers continues supporting demand for laboratory services related to pleurisy diagnosis and monitoring.

Pleurisy Market Regional Outlook

Download FREE Sample to learn more about this report.

The Pleurisy Market demonstrates significant regional variation based on respiratory disease prevalence, healthcare infrastructure, diagnostic accessibility, and thoracic care availability. North America leads with approximately 39% market share due to advanced healthcare systems and high diagnostic utilization. Europe contributes 28% through strong hospital infrastructure and widespread adoption of minimally invasive thoracic procedures. Asia-Pacific accounts for 24% of market activity, supported by growing healthcare investments and increasing respiratory disease incidence. Middle East & Africa represent 9%, driven by healthcare modernization and expanding diagnostic capabilities. Continuous improvements in imaging technologies and thoracic care services support regional market expansion.

NORTH AMERICA

North America accounts for approximately 39% of the global Pleurisy Market. The region benefits from advanced healthcare infrastructure, extensive diagnostic capabilities, and widespread access to thoracic specialists. The United States contributes approximately 84% of regional market activity, while Canada accounts for 13% and Mexico contributes 3%. More than 1.5 million pleural effusion cases are reported annually across the region. Approximately 70% of pleurisy-related diagnoses involve advanced imaging technologies, including CT scanning and ultrasound evaluation. Hospitals perform over 175,000 thoracentesis procedures annually. Respiratory infections account for nearly 40% of pleurisy-related admissions, while malignancies contribute approximately 24%. Minimally invasive thoracic surgery adoption exceeds 52% among specialized thoracic centers. More than 90% of tertiary hospitals maintain dedicated imaging facilities capable of pleural disease assessment. Healthcare providers increasingly utilize portable ultrasound systems, improving procedural guidance accuracy by approximately 20%. Research institutions and healthcare organizations continue investing in advanced thoracic diagnostics and patient management programs. The presence of specialized respiratory centers, strong reimbursement frameworks, and increasing awareness of pleural diseases continue supporting North America's leadership position within the Pleurisy Market.

EUROPE

Europe represents approximately 28% of the global Pleurisy Market and maintains a strong position due to comprehensive healthcare coverage and advanced respiratory care services. Germany contributes approximately 24% of regional demand, followed by France at 17%, the United Kingdom at 15%, Italy at 13%, and Spain at 9%. More than 800,000 pleural disease cases are evaluated annually across Europe. Approximately 76% of suspected pleurisy patients undergo diagnostic imaging during initial assessment. Chest ultrasound utilization has increased by 29% during recent years due to improved portability and diagnostic accuracy. Thoracentesis procedures exceed 300,000 annually across major European healthcare systems. Minimally invasive thoracic surgery accounts for approximately 49% of pleural intervention procedures. Respiratory diseases remain a significant healthcare burden, affecting more than 60 million individuals throughout the region. Public healthcare investments support widespread access to diagnostic services. More than 88% of tertiary hospitals maintain dedicated thoracic care programs. Digital imaging systems and advanced laboratory diagnostics are extensively integrated into respiratory disease management. Increasing adoption of precision diagnostics and minimally invasive interventions continues supporting growth within the European Pleurisy Market.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 24% of the global Pleurisy Market and represents the fastest-expanding regional healthcare segment due to rising respiratory disease prevalence and healthcare infrastructure development. China contributes approximately 42% of regional market activity, followed by Japan at 18%, India at 15%, South Korea at 8%, and Australia at 5%. More than 2 million pleural disease cases are diagnosed annually throughout the region. Respiratory infections remain a major contributor, accounting for approximately 46% of pleurisy-related diagnoses. Tuberculosis-associated pleural complications continue influencing demand in several countries, particularly within densely populated regions. Advanced imaging utilization has increased by 32% since 2020. More than 65% of major urban hospitals now provide ultrasound-guided thoracentesis services. Growing investments in healthcare modernization have expanded access to CT imaging systems and minimally invasive thoracic procedures. Hospital infrastructure continues expanding rapidly, with over 20,000 major hospitals serving respiratory patients throughout the region. Increasing healthcare expenditure, improving diagnostic awareness, and growing availability of specialized thoracic care continue supporting expansion of the Asia-Pacific Pleurisy Market.

MIDDLE EAST & AFRICA

The Middle East & Africa region represents approximately 9% of global Pleurisy Market activity. Healthcare modernization initiatives, expanding hospital infrastructure, and increasing respiratory disease awareness are driving market development. Gulf countries account for approximately 58% of regional demand, while African markets contribute 42%. More than 500,000 respiratory-related pleural disease cases are evaluated annually throughout the region. Infectious diseases contribute approximately 48% of pleurisy diagnoses, reflecting ongoing public health challenges. Diagnostic imaging utilization has increased by 26% during recent years as healthcare facilities expand radiology capabilities. Approximately 62% of major hospitals now provide thoracentesis services. Ultrasound-guided procedures account for nearly 37% of interventions, reflecting growing adoption of modern diagnostic practices. Specialized respiratory care centers continue expanding across urban healthcare systems. Government-led healthcare investments have increased access to advanced imaging technologies, including CT and ultrasound systems. More than 70% of newly commissioned tertiary hospitals include respiratory disease diagnostic units. Growing healthcare infrastructure development and increasing awareness of thoracic diseases continue supporting demand for pleurisy-related diagnostics and treatment solutions across the Middle East and Africa.

List of Top Pleurisy Companies

• Scanlan
• Sontec Instruments
• Pilling Surgical
• Integra LifeSciences
• Olympus Corporation
• Delacroix-Chevalier
• Myra
• Wexler Surgical

List of Top 2 Companies Market Share

• Olympus Corporation: Holds approximately 21% market share in pleurisy-related thoracic visualization and endoscopic equipment, supported by deployment in more than 120 countries and extensive utilization across thoracic surgery departments.
• Integra LifeSciences: Accounts for approximately 17% market share within thoracic surgical instrumentation and pleural procedure devices, supported by broad hospital adoption and a portfolio serving thousands of respiratory and surgical procedures annually.

Investment Analysis and Opportunities

Investment activity within the Pleurisy Market continues increasing due to the growing burden of respiratory diseases and pleural complications. More than 1.5 million pleural effusion cases are reported annually in major developed healthcare systems, creating sustained demand for diagnostic imaging, thoracic procedures, and monitoring technologies. Healthcare providers are investing in portable ultrasound systems, which improve bedside diagnostic accessibility by approximately 28%. More than 61% of thoracentesis procedures now utilize ultrasound guidance, encouraging procurement of advanced imaging equipment. Hospitals continue expanding thoracic care units, particularly in regions experiencing increased respiratory disease prevalence.

Minimally invasive surgical technologies present a significant investment opportunity. Video-assisted thoracic surgery reduces hospital stays by approximately 35% and lowers complication rates by 18%, making it an attractive area for healthcare investment. Diagnostic laboratory modernization is also accelerating, with automated systems improving sample processing efficiency by 24%. Emerging markets provide substantial opportunities because respiratory infections account for approximately 46% of pleurisy diagnoses in several developing regions. Investments in digital imaging, artificial intelligence-assisted diagnostics, and specialized thoracic instruments continue supporting innovation. Expanding healthcare infrastructure and increasing awareness of pleural diseases create favorable conditions for long-term market development.

New Product Development

Innovation within the Pleurisy Market is focused on imaging technologies, minimally invasive procedures, advanced thoracic instruments, and diagnostic efficiency improvements. More than 73% of complex pleural disease cases now involve advanced imaging evaluation, encouraging manufacturers to develop higher-resolution diagnostic platforms. Portable ultrasound systems have become a major area of innovation. New-generation devices reduce scanning times by approximately 19% and improve pleural fluid detection accuracy by 21%. Artificial intelligence-assisted imaging software is also gaining traction, improving lesion identification rates by approximately 17%.

Thoracic surgical instrument manufacturers continue introducing precision devices designed for minimally invasive procedures. Video-assisted thoracic surgery platforms now provide image magnification exceeding 10 times, improving procedural visibility and surgical precision. Advanced drainage systems are improving fluid management efficiency by approximately 22%. Laboratory diagnostics are evolving through biomarker-based testing approaches. Automated blood testing platforms improve throughput by approximately 24% while reducing reporting times. Digital healthcare integration further enhances diagnostic workflows through real-time imaging access and electronic reporting systems. These innovations continue improving patient outcomes and strengthening technological capabilities across pleurisy diagnosis and treatment pathways.

Five Recent Developments

• 2023: Olympus Corporation introduced an advanced thoracic visualization platform that improved surgical image clarity by approximately 20% during minimally invasive pleural procedures.
• 2023: Integra LifeSciences expanded its thoracic surgical instrument portfolio with devices designed to reduce procedural handling time by 15%.
• 2024: Pilling Surgical launched precision thoracic instruments supporting video-assisted procedures and improving operational efficiency by approximately 18%.
• 2024: Scanlan introduced upgraded pleural intervention instruments with enhanced ergonomic design, reducing surgeon fatigue by approximately 12% during prolonged procedures.
• 2025: Sontec Instruments developed advanced ultrasound-compatible thoracentesis tools that improved procedural accuracy by approximately 16% in image-guided interventions.

Report Coverage of Pleurisy Market

The Pleurisy Market report provides comprehensive analysis of diagnostic technologies, treatment procedures, clinical applications, competitive positioning, and regional healthcare trends. The study evaluates healthcare activities associated with more than 1.5 million annual pleural effusion cases in major developed healthcare systems and examines evolving approaches to pleural disease management. The report covers thoracentesis, video-assisted thoracic surgery, imaging devices, and blood testing solutions. Imaging devices account for approximately 38% of market activity, thoracentesis contributes 27%, blood tests represent 19%, and video-assisted thoracic surgery accounts for 16%. Application analysis includes hospitals with 66% share, clinics at 22%, and diagnostic laboratories at 12%.

Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa. North America leads with approximately 39% market share, followed by Europe at 28%, Asia-Pacific at 24%, and Middle East & Africa at 9%. The report evaluates more than 8 major companies active in thoracic instruments, imaging systems, and pleural intervention technologies. Technology assessment includes ultrasound-guided thoracentesis, advanced CT imaging, digital diagnostics, minimally invasive thoracic surgery platforms, laboratory testing systems, and artificial intelligence-assisted imaging tools. The report further examines investment opportunities related to respiratory disease management, healthcare infrastructure expansion, diagnostic innovation, and modernization of thoracic care services, providing detailed insight into current and future market developments.